Skip to content


  • Commentary
  • Open Access

Carrier priming to improve pneumococcal disease control and reduce the international program’s cost in children


  • Received: 22 July 2016
  • Accepted: 22 September 2016
  • Published:


Pneumococcal conjugate vaccine (PCV) has the potential to interact with other vaccines containing diphtheria toxin-like antigens (such as those found in the DTP vaccine) upon sequential administration. This is attributed to the similarity of the diphtheria toxoid antigen to the carrier protein used to make PCV, (known as cross reactive material [CRM]) to diphtheria toxin 197 or CRM197. The interaction could lead to enhanced immunogenicity of PCV as a result of a phenomenon called carrier priming, whereby DTP is given some weeks before the first dose of PCV. This phenomenon could be implemented in the immunisation schedule in developing countries and among vulnerable populations to enhance the immunogenicity of PCV, reduce the number of doses required, and produce a more cost-effective immunisation program in developing countries.


  • Pneumococcal conjugate vaccine
  • Carrier priming

Main text

Streptococcus pneumoniae is a leading cause of pneumonia and death in children worldwide [1]. It is estimated that 14.5 million episodes of serious pneumococcal disease occur each year in children aged less than five years, resulting in at least 500,00 deaths, almost all of which occur in low- and middle-income countries [2]. Vaccination has proved very successful in the control of pneumococcal disease in many developing countries and there is growing evidence for herd protection. For example, in The Gambia, infant vaccination has reduced vaccine-type pneumococcal carriage not only among vaccinated children but also among non-vaccinated older children and adults, indicating a substantial herd effect [3]. However, not all countries have introduced vaccination of infants as implementation is limited by the high cost of the vaccine [4]. The cost of one dose of pneumococcal conjugate vaccine (PCV) can be very high in developed countries (> $100) [5]. The best subsidised price for resource-poor countries has been brought down to $3 · 30 per dose [6], which is comparable to the cost of all other pediatric vaccines combined (HepB, BCG, OPV, DPT-Hib, and Measles) [7]. Therefore, there is intense interest in reducing the cost of vaccination against pneumococcal disease in young children through eg. shorter schedules of one or two doses instead of three doses [8].

The use of the 3 + 0 schedule is supported by randomised controlled clinical trials for prevention of pneumonia and invasive pneumococcal disease (IPD) in developing countries [9], and has been recommended by WHO. However, after more than a decade of using PCV in many developed countries, evidence consistently demonstrates strong herd immunity; most vaccine-type pneumococcal disease is close to elimination in children irrespective of individual vaccination status [10]. Consequently, a “1 + 1” schedule (where a booster dose is given in second year of life) has been promoted for use in developing countries where the immunisation program is mature (implemented for few years) and vaccine-type carriage is largely eliminated in the community [11]. In such mature vaccine programmes, individual protection may not be required because the probability of exposure to vaccine-type infection has become very low [10]. Therefore, a “1 + 1” schedule could be sufficient to maintain disease control, and at a considerably reduced cost [8]. Long-term protection against IPD by PCV depends on a combination of persistence of protective serum antibody levels, immunological memory, and herd immunity [12]. Additionally, and importantly, we suggest consideration of the use of carrier priming to enhance the immunogenicity, especially of the first PCV dose. Carrier priming is defined as an improved antibody response to a carbohydrate portion of a glycoconjugate vaccine because an individual has been previously primed with the carrier protein [13].

The 13-valent PCV utilises carrier protein cross-reacting material 197 (CRM197) of diphtheria toxin, which is antigenically similar to the diphtheria toxin in DTP. It is believed that priming via the carrier molecule enhances the response to conjugate vaccines by increasing the number of carrier-specific T lymphocytes; these can provide the necessary support for the expansion and differentiation of polysaccharide specific B lymphocytes [14]. Several studies have found that prior receipt of tetanus/diphtheria containing vaccine such as DTP in infants who are then administered conjugate vaccine can lead to rapid and earlier onset of clinical protection against the disease [15-17]. In developing countries, the risk of IPD peaks in the first few months of life and the current vaccine schedule is 6, 10 and 14 weeks. We propose evaluation of a schedule that offers the first PCV at ten weeks of age after prior administration of DTP vaccine at six weeks to take advantage of carrier priming [16]. If adequate priming occurs, a reduced schedule (where first PCV is given after DTP) may be sufficient and more cost-effective, particularly for resource poor settings with mature immunisation programs.



Bacille Calmette Guerin vaccine


Cross-reacting material 197


Diphtheria tetanus pertussis vaccine and haemophilus influenzae type b vaccine


Hepatitis B vaccine


Oral polio vaccine


Invasive pneumococcal disease


Pneumococcal conjugate vaccine





Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

MT searched the literature, examined available evidence and drafted the first version of the manuscript, HR provided further input to the draft, references and text structure; KM provided more insights or recent updates in the field; and RB formulated the basic idea of the comment and supervised the progress of the entire work through to the final version. All authors read and approved the final manuscript.

Competing interests

Robert Booy has received funding from Baxter, CSL, GSK, Merck, Novartis, Pfizer, Roche, and Sanofi Pasteur for the conduct of sponsored research, travel to present at conferences or consultancy work; all funding received is directed to research accounts at The Children’s Hospital at Westmead.

Harunor Rashid has received fees from Pfizer and Novartis for consulting or serving on an advisory board. The other authors have declared no conflict of interest in relation to this work.

Consent for publication

Not applicable.

Ethics approval and consent to participate

None required.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

National Centre for Immunisation Research and Surveillance (NCIRS), The Children’s Hospital at Westmead, Sydney, NSW, Australia
The Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
NHMRC Centre for Research Excellence-Immunisation in understudied and special risk populations: closing the gap in knowledge through a multidisciplinary approach, School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, Australia
Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Biological Sciences and Sydney Medical School, University of Sydney, Sydney, Australia
Murdoch Childrens Research Institute, Melbourne, VIC, Australia
London School of Hygiene and Tropical Medicine, London, UK
WHO Collaborating Centre for Mass Gatherings and High Consequence/High Visibility Events, Flinders University, Adelaide, 5001, Australia


  1. Lee LH, Gu X-X, Nahm MH. Towards new broader spectrum pneumococcal vaccines: The future of pneumococcal disease prevention. Vaccines. 2014;2:112–28.View ArticlePubMedPubMed CentralGoogle Scholar
  2. O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902.View ArticlePubMedGoogle Scholar
  3. Roca A, Hill PC, Townend J, et al. Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med. 2011;8:1361.View ArticleGoogle Scholar
  4. Torres-Rueda S, Burchett HE, Griffiths UK, et al. New pneumococcal conjugate vaccine introductions in four sub-Saharan African countries: a cross-country analysis of health systems’ impacts. Afr Health Sci. 2015;15:868–77.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Centers for Disease Control and Prevention (CDC), USA. CDC vaccine price list. Accessed 20 July 2016.
  6. UNICEF. Cost of pneumococcal vaccines (GAVI). Accessed 29 May 2016.
  7. Usuf E, Mackenzie G, Lowe-Jallow Y, et al. Costs of vaccine delivery in the Gambia before and after, pentavalent and pneumococcal conjugate vaccine introductions. Vaccine. 2014;32:1975–81.View ArticlePubMedGoogle Scholar
  8. Flasche S, Van Hoek AJ, Goldblatt D, et al. The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries. PLoS Med. 2015;12, e1001839.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Conklin L, Knoll MD, Loo J, et al. Landscape analysis of pneumococcal conjugate vaccine dosing schedules: A systematic review Sub-report on the 3-dose schedules. A project of the AVI Technical Assistance Consortium (AVI-TAC) Final Report1 0 2011. Accessed 02 May 2016.
  10. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10, e1001517.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Russell FM, Carapetis JR, Burton RL, et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine. 2011;29:535–44.View ArticlePubMedGoogle Scholar
  12. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213–20.View ArticlePubMedGoogle Scholar
  13. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine. 1996;14:1239–42.View ArticlePubMedGoogle Scholar
  14. Granoff DM, Holmes SJ, Osterholm MT, et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis. 1993;168:663–71.View ArticlePubMedGoogle Scholar
  15. Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet. 1997;349:1197–202.View ArticlePubMedGoogle Scholar
  16. Pobre K, Tashani M, Ridda I, Rashid H, Wong M, Booy R. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine. 2014;32:1423–30.View ArticlePubMedGoogle Scholar
  17. Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr. 2016;5(3):311–8.Google Scholar


© The Author(s) 2016